中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2014年
25期
90-91,96
,共3页
依斯巴汀%慢性荨麻疹%序贯疗法%临床观察
依斯巴汀%慢性蕁痳疹%序貫療法%臨床觀察
의사파정%만성담마진%서관요법%림상관찰
Ebastine%Chronic urticarial%Sequential therapy%Clinical observation
目的:观察序贯疗法治疗慢性荨麻疹的临床效果。方法选择2013年1月~2014年3月本院收治的64例慢性荨麻疹患者为研究对象,将其随机分为观察组和对照组,每组各32例。观察组先采用依斯巴汀注射液治疗,待症状减轻后,再服用依斯巴汀片治疗;对照组采用赛庚啶治疗,观察对比两组患者的临床疗效和临床指标。结果观察组的临床总有效率为75.0%,对照组为50.0%,两组差异有统计学意义(P<0.05)。观察组与对照组比较,其治疗后的瘙痒、风团数目,风团大小,持续时间差异均有统计学意义(P<0.05)。结论依斯巴汀序贯疗法治疗慢性荨麻疹的临床效果显著,值得临床推广应用。
目的:觀察序貫療法治療慢性蕁痳疹的臨床效果。方法選擇2013年1月~2014年3月本院收治的64例慢性蕁痳疹患者為研究對象,將其隨機分為觀察組和對照組,每組各32例。觀察組先採用依斯巴汀註射液治療,待癥狀減輕後,再服用依斯巴汀片治療;對照組採用賽庚啶治療,觀察對比兩組患者的臨床療效和臨床指標。結果觀察組的臨床總有效率為75.0%,對照組為50.0%,兩組差異有統計學意義(P<0.05)。觀察組與對照組比較,其治療後的瘙癢、風糰數目,風糰大小,持續時間差異均有統計學意義(P<0.05)。結論依斯巴汀序貫療法治療慢性蕁痳疹的臨床效果顯著,值得臨床推廣應用。
목적:관찰서관요법치료만성담마진적림상효과。방법선택2013년1월~2014년3월본원수치적64례만성담마진환자위연구대상,장기수궤분위관찰조화대조조,매조각32례。관찰조선채용의사파정주사액치료,대증상감경후,재복용의사파정편치료;대조조채용새경정치료,관찰대비량조환자적림상료효화림상지표。결과관찰조적림상총유효솔위75.0%,대조조위50.0%,량조차이유통계학의의(P<0.05)。관찰조여대조조비교,기치료후적소양、풍단수목,풍단대소,지속시간차이균유통계학의의(P<0.05)。결론의사파정서관요법치료만성담마진적림상효과현저,치득림상추엄응용。
Objective To observe the clinical effect of sequential therapy for treatment of chronic urticaria. Methods 64 patients with chronic urticarial treated in our hospital from Jan 2013 to Mar 2014 were selected as research objects and randomly divided into the observation group and the control group,with 32 cases in each group.The observation group was given ebastine injection first then ebastine tablet after symptom remission.The control group was given cyproheptadine.The clinical efficacy and clinical index were observed and compared between the two groups. Results The clinical total effective rate was 75.0% in the observation group and 50.0% in the control group,with statistical dif-ference (P<0.05).The observation group and the control group had statistical difference regarding pruritus,wheal number, wheal size and duration after treatment (P<0.05). Conclusion Sequential therapy with ebastine has significant clinical effect for treatment of chronic urticarial,which is worthy of clinical promotion and application.